This content is machine translated "Small Molecules" for the Treatment of Psoriasis Oral and topical drug candidates score well in studies As in today’s era of personalized medicine a treatment tailored to the individual needs of psoriasis patients is important, there are several arguments for a use of small molecule substances.…
View Post 5 min This content is machine translated Psoriatic Arthritis New long-term data on guselkumab published Phase III data on the IL23p19 inhibitor guselkumab demonstrate complete resolution of skin symptoms and positive joint effects in adult patients with active psoriatic arthritis (PsoA) lasting over two years.
View Post 6 min This content is machine translated Psoriasis as an inflammatory systemic disease Changing disease concept – implications for biologic therapy. Psoriasis is nowadays no longer understood as an exclusive skin disease, but rather as a systemic disease. Biologics specifically intervene in the disease process and have revolutionized treatment options. When…
View Post 4 min This content is machine translated Psoriatic Arthritis Another JAK inhibitor has cleared the approval hurdle In patients with psoriatic arthritis who do not respond adequately to conventional DMARDs or a biologic, the EULAR recommendations advise the use of a JAK inhibitor. Recently, upadacitinib, another member…
View Post 4 min This content is machine translated Psoriasis infestation of scalp, nails and palmoplantar Excellent long-term data – IL23 inhibitor improves symptoms and quality of life Psoriasis in highly visible locations is particularly stigmatizing for patients. There is a high demand for effective and safe treatment options, especially for severe forms of the disease. Of those…
View Post 3 min This content is machine translated Acute lumbar back pain Stay active despite back problems Back pain requires interdisciplinary approaches to solutions, this is also a conclusion of the Back Report 2020 published by the Swiss Rheumatism League. A multimodal coping strategy of lifestyle modification…
View Post 4 min This content is machine translated Small Molecules Phosphodiesterase-4 as a therapeutic target in psoriasis – an update. The oral PDE-4 inhibitor apremilast has been an established treatment option for moderate to severe chronic plaque psoriasis and psoriatic arthritis for several years. And in a phase IIb study…
View Post 7 min This content is machine translated Rheumatoid arthritis Lasting remission through targeted treatment Despite great advances in the management of rheumatoid arthritis, many patients do not respond satisfactorily (or adequately) to available treatments [1]. Data from clinical trials of a targeted disease-modifying antirheumatic…
View Post 5 min This content is machine translated Systemic treatment of psoriasis Patient-adapted choice of the appropriate biologic is crucial Selecting the appropriate treatment option among the multitude of available antipsoriatic agents is one of the greatest challenges today. Empirical studies show that the therapeutic response of different biologics varies…
View Post 5 min This content is machine translated Psoriasis therapy in pediatric patients. IL17A inhibitors effective and safe in childhood and adolescent psoriasis patients Children and adolescents with psoriasis are often significantly limited in their quality of life. There is a need for new treatment options for this patient population, especially for cases with…
View Post 23 min This content is machine translated Rheumatism and cancer Effects of cancer on rheumatoid arthritis therapy Immunomodulatory and immunosuppressive therapies in cancer patients may promote progression or recurrence of malignant disease. However, the various substances differ with regard to this risk. In addition to the careful… CME-Test
